TY - JOUR T1 - Alpha<sub>2</sub> agonist dexmedetomidine may reduce duration of delirium in critically ill adults JF - Evidence Based Nursing JO - Evid Based Nurs SP - 91 LP - 91 DO - 10.1136/ebnurs-2019-103215 VL - 24 IS - 3 AU - James Hill AU - Chandbi Sange AU - Andrew Clegg Y1 - 2021/07/01 UR - http://ebn.bmj.com/content/24/3/91.abstract N2 - Commentary on: Burry L, Hutton B, Williamson DR et al. Pharmacological interventions for the treatment of delirium in critically ill adults. Cochrane Database Syst Rev 2019:CD011749. DOI: 10.1002/14651858.Alpha2 agonist dexmedetomidine may reduce duration of delirium while Cholinesterase inhibitor rivastigmine may prolong the duration of delirium and length of intensive care.Future research should ensure that important clinical outcomes are reported such as symptom management.Delirium is a multifaceted neurocognitive indication of an underlying medical condition.1 It frequently occurs in critically ill patients and can have substantial negative consequences with increased mortality and intensive care unit (ICU) length of stay.2 Uncertainty remains around the effectiveness of pharmacological interventions for the treatment of delirium within ICU.3 This Cochrane systematic review aims to examine the effectiveness of pharmacological interventions for treating delirium in critically ill adults with a confirmed or documented high risk of delirium.3 … ER -